Federal Judge Questions Marijuana-Gun Link Amid State Legalization
A federal judge challenged the constitutional basis for barring cannabis users from firearm ownership, citing widespread state-level legalization.

A judge in a courtroom holding a gavel, focused on legal documents.
Federal Statute Faces Constitutional Scrutiny
The unnamed federal judge challenged the continued enforcement of 18 U.S.C. § 922(g)(3), which prohibits unlawful users of controlled substances from possessing firearms, in a ruling that acknowledged the tension between federal gun law and state cannabis policy. The statute has applied to cannabis users since the Controlled Substances Act classified marijuana as a Schedule I drug in 1970. But the judge's opinion marks a rare judicial acknowledgment that state legalization may undermine the federal government's historical justification for the prohibition.
The case adds to mounting legal pressure on § 922(g)(3) following the Supreme Court's 2022 decision in New York State Rifle & Pistol Association v. Bruen, which established that gun restrictions must align with historical tradition. Several circuit courts have since questioned whether the founding-era understanding of "dangerous persons" extends to individuals who use a substance legal in their home state.
State Legalization Creates Federal-State Collision
Thirty-eight states have legalized medical or adult-use cannabis, creating a regulatory environment where millions of Americans lawfully purchase marijuana under state law while remaining federal felons if they simultaneously own firearms. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) Form 4473, required for all gun purchases, explicitly asks buyers whether they're unlawful users of marijuana. It warns that state-legal use doesn't exempt federal prosecution.
The judge's opinion didn't specify whether the ruling applies to medical patients, recreational users, or both categories. Medical cannabis patients number approximately 3.2 million across state programs. Adult-use markets serve tens of millions of consumers in states including California, Colorado, and Michigan.
Circuit Split Deepens on Post-Bruen Analysis
Federal appellate courts remain divided on whether § 922(g)(3) survives Bruen's historical-tradition test. The Fifth Circuit in 2023 struck down the statute as applied to a marijuana user in United States v. Daniels, while other circuits have upheld it. The Fifth Circuit held that the government failed to prove a founding-era tradition of disarming individuals based solely on substance use, absent evidence of dangerousness or mental incapacity.
Justice Department lawyers have defended § 922(g)(3) by arguing that intoxicating substances historically justified firearm restrictions, citing 19th-century laws targeting habitual drunkards. Critics counter that marijuana's modern legal status and lower impairment profile compared to alcohol undermine the analogy. The Supreme Court hasn't yet granted certiorari in any post-Bruen cannabis-gun case, leaving the circuit split unresolved.
Enforcement Data Shows Thousands Prosecuted Annually
Federal prosecutors charged approximately 1,800 defendants under § 922(g)(3) in fiscal year 2024, according to U.S. Sentencing Commission data, with the majority involving marijuana rather than other controlled substances. Enforcement has historically targeted individuals who come to law enforcement attention through unrelated incidents: traffic stops, domestic disputes, or probation checks. Proactive ATF sweeps of dispensary customer lists remain rare.
The median sentence for § 922(g)(3) convictions was 24 months in 2024, though first-time offenders with no aggravating factors often receive probation. Defense attorneys have increasingly filed Bruen-based motions to dismiss in pending cases. Success rates vary widely by district.
Industry and Advocacy Groups Monitor Case
Cannabis trade associations and Second Amendment advocacy organizations have both filed amicus briefs in related cases, arguing that the prohibition forces law-abiding citizens to choose between state-legal medicine and constitutional rights. The National Organization for the Reform of Marijuana Laws (NORML) has documented dozens of cases where medical patients faced prosecution after reporting crimes or seeking police assistance, only to have officers discover firearms during subsequent investigations.
For full background on this legal conflict, see the CannIntel topic hub on marijuana and gun rights. The case name, docket number, and circuit court weren't disclosed in the initial reporting. The judge's ruling doesn't appear to have been published on PACER as of July 11, 2026. Details on the scope of the opinion remain unavailable: whether it applies to pending prosecutions or establishes a binding standard.
The next procedural step will likely depend on whether the Justice Department appeals the ruling or whether the judge's opinion was issued in a pretrial motion rather than a final judgment. Federal defenders in jurisdictions with legal cannabis markets are expected to cite the opinion in pending suppression motions and sentencing memoranda.
For complete background, history, and our ongoing coverage of this story:
Open the CannIntel topic hub →Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Laws

Indian Editorial Urges Cannabis Reform as Policy Debate Gains Ground
The Statesman calls for India to reconsider cannabis prohibition amid growing global momentum for legalization.

Ohio Judge Blocks Hemp THC Cap on Dormant Commerce Clause Grounds
A federal court halted Ohio's 0.3% total-THC limit for hemp products, finding it likely violates interstate commerce protections.

NORML Intern Draws Parallels Between Alcohol, Cannabis Prohibitions
Summer intern Caroline Breen outlines structural failures shared by both 20th-century prohibitions in policy analysis.
More from the newsroom

Cannabis Treatment Cuts Agitation in Hospice Dementia Patients, Trial Finds
A cannabis-derived therapy reduced severe agitation in hospice-eligible dementia patients in a controlled trial published this week.

Curaleaf Eyes Spain's New Cannabis Framework for EU Pharma Push
The MSO is positioning its European subsidiaries to capitalize on Spain's regulatory shift toward medicinal cannabis.

Small Minnesota City Pauses Funding for Government-Owned Dispensary
A Minnesota municipality has suspended capital allocations for its planned public-sector cannabis retail facility amid budget concerns.